Related Experiment Videos
Temelimab versus placebo in patients with post-COVID condition
Mayssam Nehme1, Margret Hund-Georgiadis2, Esther Del Corral Beamonte3
1Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Brain, Behavior, and Immunity
|July 6, 2026
Summary
This study investigated Temelimab as a treatment for long COVID fatigue. Results showed no significant difference in fatigue improvement between Temelimab and placebo groups after 24 weeks.
Area of Science:
- Immunology
- Neurology
- Infectious Diseases
Background:
- Post-COVID condition affects over 400 million globally, impacting quality of life.
- Long COVID symptoms include fatigue, cognitive issues, and mood disorders.
- Temelimab, an antibody targeting HERV-W ENV, is explored for post-COVID treatment.
Purpose of the Study:
- To evaluate the efficacy of Temelimab in treating persistent symptoms of post-COVID condition.
- To assess the impact of Temelimab on fatigue, cognition, mood, and quality of life.
- To determine the safety and tolerability of Temelimab in long COVID patients.
Main Methods:
- A 24-week randomized, double-blind, placebo-controlled trial.
- 203 adults with post-COVID fatigue and HERV-W-ENV positivity were enrolled.
- Participants received monthly IV infusions of 54 mg/kg Temelimab or placebo.
Main Results:
- No significant difference in fatigue reduction (PROMIS Fatigue SF 7a) between Temelimab and placebo groups at 24 weeks.
- Temelimab group showed a 3.2-point decrease, while placebo showed a 3.8-point decrease.
- Secondary endpoints including cognition, anxiety, and depression also showed no significant differences.
Conclusions:
- Temelimab did not demonstrate significant improvement in fatigue for adults with persistent post-COVID symptoms compared to placebo.
- The study did not find significant benefits in secondary outcomes for the Temelimab group.
- Further research may be needed to explore alternative treatments for long COVID.
Related Concept Videos
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:17Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
01:28Pleural Effusion II: Symptoms and Management
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...